ANTIMICROBIAL RESISTANCE –RESEARCH AND DEVELOPMENTDr Jenny FirmanPrincipal Medical Adviser, Office of Health ProtectionAustralian Government Department of Health

Australia’s First National AMR Strategy 2015-2019

• Objective Five: Agree a national research agenda and promote investment in the discovery and development of new products and approaches to prevent, detect and contain antimicrobial resistance

1

NHMRC Funded CREs – AMR Category Name Ends

University of Queensland

REdefining antimicrobial use to reDUceresistanCE (REDUCE). 2019

University of Melbourne

A National Centre for Antimicrobial Stewardship: Using a One Health Approach

2019

Bond UniversityMinimising Antibiotic Resistance for Acute Respiratory Infections (CREMARA) 2017

Queensland University of Technology

Reducing Healthcare Associated Infections (CRE-RHAI) 2017

11 July, 2017 *Source – NHRMC Research Funding 2014-2016, publicly available dataset 2

11 July, 2017 3

CREMARA REDUCE

NCAS RHAI

Delayed prescribing

Development of guidelines

Diagnostic tests and biomarkers

Cost effectiveness

studies

Modelling of novel

antimicrobial dosages

Optimisation of antibiotic therapy

Shared decision making and

patient decision aids

One Health AMS

Antimicrobial stewardship

Antimicrobial prevalence

studies

Modelling transmission

dynamics

Effective IPC interventions

and policy

Combined research themes

AMR RESEARCH

4

5

Research in animal health & agriculture

Medical Research Future Fund

• The Medical Research Future Fund (MRFF) supports health and medical research and innovation.

• The MRFF Strategy has a focus on the entire research system – from public health to laboratory-based research, through to health systems research and the translation of findings into health system outcomes and/or commercial products.

6

Medical Research Future Fund - AMR

7

International +++++

8

National AMR Strategy – Research needs

• Novel therapeutics, including antimicrobials, adjunct treatments, combination therapies and vaccines

• Developing rapid and point-of-care diagnostic technologies • Intervention strategies to prevent the development and

transfer of resistance across species and settings • Best-practice in antimicrobial stewardship and infection

prevention and control; and• Evidence-based key messaging to promote behaviour

change to support improved prescribing practice and the use of antimicrobials.

9

Key knowledge gaps - ASTAG

• Behavioural drivers of antimicrobial usage and effective approaches to support appropriate use across the antimicrobial supply chain.

• Economic cost burden of AMR in Australia ( human and animal).

• Targets for antimicrobial usage and prevalence rates of resistant organisms to measure impact and drive behaviour change.

• Develop point of care testing for better diagnosis and therapy

• Development of new products including new vaccines, repurposing old antibiotics

10

Next Steps

11

• AMR website will provide greater visibility to the range of AMR related research projects that are currently in progress.

• Identify how we can address research questions in partnership

12

QUESTIONS?